CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion
2020年08月17日

SHANGHAI, Aug. 17, 2020 /PRNewswire/ -- CARsgen Therapeutics, a leader in developing novel CAR-T cell therapies against solid tumors, today announced its publication of the 7×21 CAR-T technology in CLINICAL CANCER RESEARCH. The article is titled "Coexpression of IL-7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion."